U.S. regulators approve targeted pancreatic cancer drug shown to improve survival rates
The U.S.
Food and Drug Administration has approved Revolution Medicines' targeted drug for adults with metastatic pancreatic cancer who have received prior treatment or cannot receive combination chemotherapy.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.cbc.ca — the content belongs to CBC Health.
